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Abstract 
 
Aim: The objective of this study was to provide an analysis of the factors which have a 
significant impact on the growth of public expenditure on medical products in Bulgaria.  
Methods: This research work consists of a critical analysis of the data reported by the 
National Health Insurance Fund in Bulgaria on the stability of the healthcare insurance model 
and the implementation of the budget for 2014. 
Results: The results from the current analysis indicate that the growth of public expenditure 
is directly proportional to the number of reimbursed medical products and that the pattern of 
prescriptions including the innovative medical products mainly for the treatment of 
oncological and rare diseases has a significant impact on it.  
Conclusion: The reasons for the increase of public expenditure in Bulgaria include the non-
transparent decisions in pricing and reimbursement of the products, the lack of guidelines for 
presenting pharmacological evidence and the lack of legislatively-defined drug policies for 
the management and control of the patterns of medical prescriptions. 
 
Key words: Bulgaria, drug policies, reimbursement, public expenditure.  
 
Conflicts of interest: None. 
 
  
Vekov TY, Aleksandrova-Yankulovska S. Public expenditure and drug policies in Bulgaria in 2014 (Original 
research). SEEJPH 2015, posted: 27 May 2015. DOI 10.12908/SEEJPH-2014-48  
 
3 
 
Introduction  
Healthcare in the European Union (EU) countries including Bulgaria is funded by the 
healthcare systems and/or through general taxation. The main objective of the healthcare 
systems is the protection of public health, based on the principles of solidarity and universal 
access. The drug policy in every country is part of the healthcare policy and adopts the same 
objectives and principles (1). The expenses on medical products are an important component 
of the healthcare budgets of all the EU member states. There is an increasing necessity to 
limit the escalating expenses on healthcare including those on medical products, as well as 
the effective spending of the financial resources (2). 
The good European practice on drug policy implies the determining of Positive Drug Lists 
(PDL) provided by the healthcare system, and the regulation of the drug prices in a certain 
order. 
The main focus of the approaches to drug policies includes the rational use of medical 
products, which contributes to the control of public expenditure (3). Considering the fiscal 
impact of the economical and financial crisis, as well as the expected healthcare expenses for 
the aging population, these policies are of an increasing interest to the institutions which pay 
for the public expenses in healthcare (4). 
The contemporary views of the European healthcare policies are that through the correct 
regulation of the pharmaceutical markets economies can be achieved, without having an 
impact on the provision of care (5). 
The drug policy in Bulgaria is legally established by the Ministry of Health and practically 
applied by the National Council on Prices and Reimbursement of Medical Products 
(NCPRMP). This is the authority which regulates the prices and makes decisions regarding 
the reimbursement of the medical products with public funds. The control on prices is based 
on external and internal reference pricing and regressive margins for distributors and 
pharmacies. The reimbursing decisions are formally based on pharmaco-economic 
valuations, but the experts’ reports are not available to the public and the objectivity of these 
decisions cannot be established.   
In this context, the aim of this study was to analyze the public fund expenses on medical 
products in Bulgaria in 2014 in order to determine the impact of the legislative approaches to 
drug policies and their possible impact on public health. 
 
Methods 
This article is a critical analysis of data from the report of the National Health Insurance Fund 
(NHIF) in Bulgaria on the stability of the healthcare insurance model and the implementation 
of the budget for 2014 (6). A commentary is provided concerning the existing prescribing 
patterns, national policies for the inclusion of medical products in PDL and their impact on 
the increasing public expenses. A detailed analysis of the expenses by disease groups and the 
pattern for the prescription of medicines is also provided.  
All graphs and tables included in this article are created on the basis of the data derived from 
the report of the NHIF in Bulgaria on the stability of the healthcare insurance model and the 
implementation of the budget for the year 2014 (6).  
The difference of costs and amount of reimbursed products in the PDL for the period under 
investigation is presented as a percentage and is calculated with a mathematical method based 
on the determination of proportionality coefficients.  
When trying to predict the future value, one follows the following basic idea: 
 
future value = present value + change 
 
From this idea, we obtain a differential, or a difference equation by noting that: 
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change = future value – present value 
 
The growth of public expenses is influenced by a number of factors discussed in the report of 
the NHIF in Bulgaria on the stability of the healthcare insurance model and the 
implementation of the budget for 2014 (6).  
All prices are given in BGN with current exchange rates of: 1.95583 BGN = 1 EUR.  
 
Results    
The review of the development of the PDL in Bulgaria in the past three years (2011-2014) 
from the viewpoint of quantitative indicators shows a big volume (1997 medical products) 
and a list with frequent changes (every 15 days).  
In 2011, the PDL included 1382 medical products, in 2012 it included 1673 products, and in 
2014 there were 1997 products. During this three-year period, the number of reimbursed 
medical products increased by 45%.  
The proportion of public expenditure and the number of reimbursed medical products is 
presented in Figure 1. The established relationship is directly proportional, whereas the cost 
of public expenses increased by 25%.  
 
Figure 1. Reimbursed medicines for home treatment and the cost of public expenses (both in 
BGN) in Bulgaria; data for 2014 consists of estimates (Source: NHIF Report for June 2014) 
 
 
 
 
The other factor which has a marked impact on public expenditure is the pattern of 
prescription of the medical products. The presented results (Figure 2) of the average cost of 
public expenditure for the treatment of non-insulin diabetes in 2013 are indicative – the cost 
of the expense differs doubly in the various regions, considering that the list of the medical 
products, their prices and the reimbursed amounts are the same for all the regions of Bulgaria.  
The different cost of public expenses in the various regions of Bulgaria directly depends on 
the level of prescribing of DPP-4 inhibitors and GLP-1 receptor antagonists. These are the 
two groups of innovative medical products for the oral therapy of diabetes, which are rather 
recommended as a second and a third line of treatment, due to unclear data for the long-term 
cost effectiveness and doubts about the safety profile (7). 
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Figure 2. Average cost per patient (in BGN) for the treatment of non-insulin dependent diabetes 
in Bulgaria in 2013 (Source: NHIF Report for June 2014) 
 
 
 
 
The analysis of public expenses by groups of diseases outlines the clear tendencies for an 
abrupt increase in the expenses for the treatment of rare diseases and oncological diseases.      
The expenses for the treatment of rare diseases increased by 36% in 2013 compared to 2012 
and reached 59 million BGN, which constitutes 10.7% of all public expenses for medical 
products (Table 1). This points to a pronounced imbalance of solidarity in the insurance 
system, because these public costs are absorbed by only 0.15% of the insured individuals. At 
the same time, public expenses for socially significant diseases such as the cardiovascular 
disease, diseases of the neural system and diseases of other systems are decreasing (6). These 
results are an expression of the flaws in the drug policy, part of which are the application of 
internal reference pricing without a system for the control of medical prescriptions (8), the 
lack of transparency in the decisions on pricing and reimbursement, based on an expert 
evaluation of pharmaco-economical evidence, the lack of a defined limit of public expenses 
for one gained Quality-Adjusted Life Year (QALY), and the like (9). 
 
Table 1. Expenses for the treatment of rare diseases in 2013  
(Source: NHIF Report for June 2014) 
 
Disease Public expense 
Average annual cost 
per patient in BGN 
Number of 
patients 
Haemophilus 20 009 544 5290 3783 
Beta-thalassemia 8 323 230 3692 2254 
Gaucher disease 8 196 183 32 795 250 
Blonhopulmonal 
Dysplasia 
4 245 087 2828 1501 
Mukopolizaharoidosis 3 294 574 68 637 48 
Hereditary amyloidosis with 
neuropathy 
1 625 885 27 098 60 
Pompe disease 477 953 47 795 10 
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The analysis of the expenses on the medical therapy for oncological diseases, paid outside the 
cost of clinical pathways emphasizes several main facts:                 
 The expanding of the indications for innovative medicines, mainly for monoclonal 
antibodies and tyrosine kinase inhibitors. However, there is no data on the evaluation 
of the efficacy, benefits and costs of the new indications. 
 The addition of monoclonal antibodies to the target therapies, which increases the cost 
of the therapy more than 30 times, while the benefits, expressed as final health 
outcomes, are minimal. The willingness of society to pay such a high price for the 
gain of a QALY remains uncertain. 
 The inclusion of new international non-proprietary names in the PDL without a clear 
evaluation of their differential cost-effectiveness as compared to the existing 
therapies.  
As a result of all these factors, the public expenditure on oncological medical products 
significantly exceeded the settled budgets for the past years, as indicated in Table 2. 
 
Table 2. Expenses of the medical therapy for oncological diseases, paid outside the costs of 
clinical pathways (Source: Report on the implementation of the budget of NHIF, 2013-2014) 
 
YEAR  
YEAR 
2013 2014 
Budget in BGN       90 000 000 145 000 000 
Public expenditure in BGN 172 443 480 203 472 732* 
Relative share of the 
overspending (%) 
91,60 40,30 
 
*
 Data for 2014 consists of estimates.  
 
 
Discussion 
Several main factors have been identified which have an impact on the annually increasing 
public expenses on medical products in Bulgaria:  
 Non-transparent decisions for the inclusion of medical products in the PDL with 
unclear cost-effectiveness compared to the existing drug alternatives. There is no data 
on the recommendations of NCPRMP for the pharmaceutical industry and set out 
denials for reimbursement justified by the lack of sufficient evidence of effectiveness 
and/or high prices. The practice in the economically developed countries is different. 
For example, the Committee for the Evaluation of Medicinal Products in Canada 
refused to reimburse Pemetrexed for the treatment of malignant pleural mesothelioma, 
because the product does not provide added value for the price difference compared to 
the existing alternatives (10). 
Another Canadian solution sets to reimburse Sunitinib for the treatment of metastatic 
renal cell carcinoma only after negotiating the price because of poor cost-
effectiveness, despite the improved efficacy over the existing therapeutic alternatives. 
Many similar negative decisions regarding the reimbursement of medical products for 
a specific diagnosis can be found in the scientific literature. Their aim is both to 
facilitate the access of patients to therapies which give them additional therapeutic 
value and use, as well as to protect patients from health risks connected to severe 
adverse drug reactions (11,12). 
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 The lack of legally defined public expenditure related to one gained QALY. This is a 
widely used instrument for limiting public expenditure and for the control of the 
innovative medical therapies (13). 
 Lack of legal control on the patterns of prescribing medicines. The EU states have a 
number of measures in working order for improving the patterns of prescribing 
medicines. Most often they entail the monitoring of the prescriptions, 
recommendations and guidelines of advisory/obligatory nature regarding the 
prescriptions, including the requirements to prescribe an international non-proprietary 
name, a maximum limit on the prescribed medicines, prescription quotas, financial 
incentives, as well as educational and informational approaches (14-16). 
The aim of all enumerated policies is to promote the rational use of medical products for the 
benefit of public health. The combinations of diverse measures, as electronic monitoring in 
prescription and in guidelines, connected with electronic systems which support the process 
of decision-making and give feedback to the physician, are an effective way to improve the 
patterns in prescribing medicines (17). In addition, educational and informational instruments 
should be activated.          
The prescription of international non-proprietary names and prescription quotas, if possible in 
combination with target budgets and financial incentives, seem to be effective tools for the 
purpose of regulating public expenditure. 
 
Conclusion  
The effectiveness of public expenditure in Bulgaria will improve when it becomes the main 
objective in medical policy, i.e., when medical therapies are evaluated in a real and 
transparent way as a ratio of expenses and use as compared to the existing alternatives. It is 
necessary that the first steps are aimed at developing a control system of the prescription and 
evaluation of medicines’ pharmaco-economical evidence, as well as determining public 
expenditure of the medical therapy at the level of one gained QALY. 
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